Long-term therapeutic success with multimodal therapy in aggressive prolactinoma

Endocrinol Diabetes Nutr (Engl Ed). 2019 Aug-Sep;66(7):464-466. doi: 10.1016/j.endinu.2019.01.002. Epub 2019 Feb 21.
[Article in English, Spanish]
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cabergoline / administration & dosage
  • Combined Modality Therapy
  • Disease Progression
  • Female
  • Humans
  • Hydrocortisone / administration & dosage
  • Hypophysectomy*
  • Magnetic Resonance Imaging
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Neoplasm Recurrence, Local / therapy
  • Peptides, Cyclic / administration & dosage
  • Pituitary Neoplasms / diagnostic imaging
  • Pituitary Neoplasms / pathology
  • Pituitary Neoplasms / therapy*
  • Prolactinoma / diagnostic imaging
  • Prolactinoma / pathology
  • Prolactinoma / therapy*
  • Radiosurgery*
  • Somatostatin / administration & dosage
  • Somatostatin / analogs & derivatives
  • Temozolomide / administration & dosage
  • Thyroxine / administration & dosage
  • Treatment Outcome

Substances

  • Peptides, Cyclic
  • lanreotide
  • Somatostatin
  • Cabergoline
  • Thyroxine
  • Hydrocortisone
  • Temozolomide